The test will help you choose a cure for cancer

Japanese researchers have developed a special test by which you can check how the patient will respond to imatinib - standard cure for blood cancers. This will greatly assist physicians in the treatment of leukemia.

Such a test will become an indispensable tool for determining tactics treatment of leukemia . It is known that the condition of patients with blood cancer is rapidly deteriorating, if they get the wrong treatment.

Japanese scientists have created a test to check the reaction of the patient with chronic myeloid leukemia in the   imatinib Which is produced by Novartis for the therapy of tumor diseases and other blood cancers. Imatinib   blocks the enzymes of cancer cells instead of killing all rapidly proliferating cells in a row.

"The majority of patients with chronic myelogenous leukemia are sensitive to imatinib But during treatment they may develop resistance - said Yosuke Both, professor at the School of Medicine at the University of Hokkaido. - Even if the patient develops resistance, the most important question for the physician is the choice of a new drug. Here irreparable can happen - if the patient's transfer to a different medicine, from which he also has a stable, it will be a heavy blow to his health and the loss of precious time. "

Japanese doctors test allows to find the most optimal drug dosage or its combination with other drugs, which would be an important step forward in the development of the individual tumor therapy for all patients.

Industry News

Go back to the main page